Interesting post from Yahoo board. I don't do stats and
Interesting post from Yahoo board. I don't do stats and went to law school because there was no math, but this all seems good to me. Posted originally by Ross on Yahoo.
I would like to share some statistics with you that have a bearing on the likely outcome of the CD12 trial. I am a doctor who is part of a large hospital network. In our state right now, the most recent statistics show that 67% of the patients in the ICU are on mechanical ventilation. That would place them in the critical category for the CD12 trial. This is an important statistic because we know that the mortality rate in this population was reported to be as high as 80% in the beginning of the pandemic and is probably still at least 35% or higher. If we assume that most or all of patients enrolled in CD12 came from the ICU you can apply the following math:
394 patients in trial
67% critical and 33% severe
394 x 0.667 = 262 critical patients
394 x .333 = 132 severe patients
Now, conservatively assume 40% mortality rate in critical and 15% in severe
262 Critical x 40% mortality rate = 105 expected deaths
132 Severe x 15% expected mortality rate = 20 expected deaths
Total deaths should have been 105 + 20 = 125 for a 31.7% death rate if Leronlimab did not work at all and placebo group was the same as treatment group. Instead, we saw 87 deaths. Assume 90 total since people may have died after we were told 87. That means we had 35 fewer deaths than expected.
The ratio of LL to placebo was 2:1 in the trial, so the number of people treated was 262. Expected deaths in the treatment group is 262 x .317 = 83. However, according to our calculations, we had 35 fewer deaths than expected. If this difference was all due to Leronlimab, the actual deaths in the treatment group were 83-35=48. That would leave 42 deaths in the placebo group. These number represent a statistically significant difference with p<0.05.
Since these are conservative estimates of mortality in each group, this is another indication that we will get very good results from CD12 IMO.
13
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...
Continue Reading
When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...
Continue Reading
America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...
Continue Reading
Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...
Continue Reading
Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...
Continue Reading
In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...
Continue Reading
Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...
Continue Reading
Top 5 Most Recently Viewed Articles
Le Monde Gourmand Expands into the UK Market Fragrance enthusiasts in the UK have some delightful news to celebrate! Le Monde Gourmand has officially launched at a leading online retailer. With a diverse range of indulgent scents to choose from, customers can finally enjoy the luxury of these unique fragrances. A Treasure Trove of Scents Le Monde Gourmand's collection...
Continue Reading
Landmark Decision for Fashion Footwear LLC In a landmark decision that has the potential to reshape the dynamics of the fashion licensing landscape, a New York Appellate Court has decisively ruled in favor of Fashion Footwear LLC, stating that the actions of US Pony Holdings ("Pony"), an affiliate of Iconix Brand Group, to terminate their exclusive footwear license were...
Continue Reading
Vertical Bridge Partners with Verizon for Massive Tower Acquisition Vertical Bridge REIT, LLC, a notable name in communications infrastructure, has secured a significant agreement with Verizon Communications Inc. This $3.3 billion transaction gives Vertical Bridge exclusive rights to manage and operate over 6,300 wireless communication towers across the country. This...
Continue Reading
Understanding the Salary Benchmarks for TD Professionals Recent ATD research delves into the compensation and benefits of Training and Development (TD) professionals. In 2025, the overall average salary for TD professionals reached $101,229, while the median salary stood at $95,000, as indicated by the latest findings from ATD. Key Findings from the ATD Salary Report TD...
Continue Reading
Inventiva Announces Preparatory Documents for Shareholders Daix, France; New York City, NY – Inventiva (Euronext Paris and Nasdaq: IVA) is a clinical-stage biopharmaceutical company dedicated to developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH). They have recently made available key preparatory documents for their Combined General...
Continue Reading
